Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan/Cisplatin vs Etoposide/Cisplatin in ED-SCLC
NCT00349492Phase 3Completed
- Sponsor
- Clinical Research Center for Solid Tumor
- Start
- Jun 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of irinotecan in small cell lung cancer (SCLC) (2 arms), sponsored by Clinical Research Center for Solid Tumor. Primary endpoint: Overall Survival. Started Jun 2006; status: completed.
02
Drugs
irinotecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00349492.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349492.